At its Annual General Meeting on April 29, 2026, Sanofi appointed Belén Garijo as Director and Chief Executive Officer, effective May 1, 2026. Garijo brings extensive experience in healthcare leadership and R&D, having previously led Merck's transformation and held senior roles at Sanofi. The company aims to strengthen execution discipline, refine capital allocation, and enhance scientific innovation under her leadership. The meeting also approved a €4.12 per share dividend and welcomed new board members, including Christel Heydemann, CEO of Orange.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
